The EDC is live today — see what ships now
All studies
NCT07608796From ClinicalTrials.govRecruiting

JAK Signaling in Depression and Cognition in Male Football Players

  • Depressive Symptoms
  • Cognitive Symptom

At a glance

Phase
Phase 2
Study type
Interventional
Sponsor
Emory University
Enrolment target
30
Started
October 2026
Main results due
October 2027
Study sites
3
Registry updated
24 September 2026

Can you take part?

  • Ages 30 years to 55 years.
  • Men only.
  • Healthy volunteers can take part.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria
Inclusion Criteria:

* willing and able to give written informed consent
* males
* playing tackle football for at least 11 years
* 30-55 years of age
* Current Diagnostic and Statistical Manual (DSM)-V major depression or Bipolar, depressed type; or DSM-V major depression or Bipolar, depressed type in partial remission as diagnosed by the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (SCID)-V
* score of \>10 on the PHQ-9 from screening and HAM-D score ≥16 for study entry
* off all antidepressant or other psychotropic therapy (e.g., mood stabilizers, antipsychotics, and sedative hypnotics) for at least 4 weeks before baseline visit (8 weeks for fluoxetine) or on a stable psychotropic regimen for at least 4 weeks (and no planned changes)
* CRP ≥3 mg/L
* PHQ-9 anhedonia (item #1) and cognitive (item #7) scores ≥2

Exclusion Criteria:

* current or history of past autoimmune disorder
* history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection
* history of any type of cancer requiring treatment with more than minor surgery
* unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG, and laboratory testing)
* significant hematological abnormalities at screening (ANC \< 1500, Hgb\<10, platelet\< 100,000)
* history of progressive multifocal leukoencephalopathy
* history of deep venous thrombosis
* history of cardiovascular disease (coronary artery disease, congestive heart failure, stroke - controlled hypertension is OK)
* major surgery within 6 months before screening, or will require major surgery during the study
* current or recent (\<4 weeks before study start) viral (including COVID-19), bacterial, fungal, or parasitic infection, or any other active or recent infection
* symptomatic herpes zoster infection at or within 12 weeks of study start
* history of disseminated/complicated herpes zoster (for example, ophthalmic zoster or CNS involvement)
* cirrhosis of the liver from any cause
* Additional exclusion criteria apply

What this study is about

In the sponsor’s own words, from the registry.

This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 11 years of organized tackle football. This will be evaluated using a medication called baricitinib, which blocks one aspect of inflammation.

Study sites(3)

  • Emory Clinic, Emory University Hospital

    Atlanta, Georgia, United States

    Recruiting

  • Emory School Of Medicine

    Atlanta, Georgia, United States

    Recruiting

  • Emory University

    Atlanta, Georgia, United States

    Recruiting

Showing 3 of 3 sites. 3 of the 3 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT07608796. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me
JAK Signaling in Depression and Cognition in Male Football Players | Trialion